New agreement with GSK provides new medicines, saves millions for New Zealand

11 December 2013

A new agreement with the local subsidiary of UK pharma giant GlaxoSmithKline (LSE: GSK) by New Zealand’s Pharmaceutical Management Agency PHARMA will see two newly listed medicines, improved access to commonly used asthma inhalers, and millions of dollars of savings.

The agreement with GSK includes five products, three of which – the asthma inhalers fluticasone (Flixotide), salmeterol (Serevent) and the combination inhaler Seretide – are already funded. Altogether, the changes will produce savings greater than NZ$20 million ($16.5 million) over five years, according to the Agency.

PHARMAC will remove the Special Authority criteria from Seretide, which is currently used by 74,000 New Zealanders with chronic asthma, which will mean anyone whose doctor thinks they need it can have it funded.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK